Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is in a strong position for success with their focus on treating TRD, a potential for high sales, partnerships, and a strong financial position. With Breakthrough Therapy designation and a CNPV from the FDA, the company has a good chance of approval and commercialization, and risks to achieving this potential include clinical development, competition, and government regulations.

Bears say

Compass Pathways is a biotechnology company that is focused on developing therapies for mental health conditions through the use of their proprietary drug, COMP360, in combination with psychological support. While their development program follows rigorous guidelines and the drug has shown promising results in clinical trials, there are potential challenges with administration and infrastructure requirements that could hinder commercial success. In addition, there are risks associated with FDA and government regulatory oversight, manufacturing, reimbursement, competition, and financing that could impact the company's performance.

COMPASS Pathways (CMPS) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Strong Buy based on their latest research and market trends.

According to 9 analysts, COMPASS Pathways (CMPS) has a Strong Buy consensus rating as of Jun 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.